Analgesic Effects of Transversus Thoracic Plane (TTP) Block in Cardiac Surgery
Keywords
Abstract
Description
In February 2015, Ueshima et al published an article regarding ultrasound guided transversus thoracic muscle plane (TTP) block for breast cancer resection. In this article, he showed that branches of the intercostal nerves (Th2-6) dominate the region of the internal mammary area. By administering local anesthetics between the internal intercostal and transversus thoracic muscle, analgesia in the anterior chest and sternum can be obtained. A cadaveric study shows injectate spread from the second to fifth intercostal spaces with a single 15mL injection between the third and fourth ribs next to the sternum. They further published a case series of two patients who successfully underwent median sternotomy for aortic valve replacement and thymoma resection using only the TTP block for analgesia. Fast- track cardiac surgery is now widely practiced, and evidence for its safety and efficacy has spurred its adoption. With the increased demand for health care resources including nursing manpower and ICU beds, postoperative patients are returning to the cardiac surgery intensive care unit (CSICU) on shorter acting anesthetic agents so that they can be awakened, following commands and spontaneously ventilating earlier. The TTP block fits in well with the fast- track paradigm. By providing adequate analgesia for median sternotomy, the TTP block may reduce narcotic requirements and consequent sedation and respiratory depression, hypercapnia and respiratory acidosis, prolonged mechanical ventilation and need for emergency advanced airway interventions.
Dates
| Last Verified: | 08/31/2017 |
| First Submitted: | 04/08/2017 |
| Estimated Enrollment Submitted: | 04/23/2017 |
| First Posted: | 04/24/2017 |
| Last Update Submitted: | 08/31/2017 |
| Last Update Posted: | 09/04/2017 |
| Actual Study Start Date: | 09/30/2017 |
| Estimated Primary Completion Date: | 04/30/2018 |
| Estimated Study Completion Date: | 04/30/2018 |
Condition or disease
Intervention/treatment
Procedure: The nerve block group
Drug: Hydromorphone Hydrochloride
Drug: Aspirin
Drug: Acetaminophen
Drug: Fentanyl
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: The nerve block group TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen) | Procedure: The nerve block group The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient. |
| Active Comparator: The standard of care group Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen. |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - patients undergoing cardiac surgical procedures performed by a single conventional median sternotomy, and first case of the day patient because early postoperative pain scores are difficult to obtain overnight for patients admitted to the ICU in the evening. Exclusion Criteria: - patients undergoing non-median sternotomy access, surgeries involving saphenous vein or radial artery harvests, emergency cases, LVEF (Left ventricular efection fraction) <30%, ASAPS (American society of anesthesiologists physical status)=5, known local anesthetic allergy, allergy to any study medications, pre-existing major organ dysfunction including hepatic and renal failure, eGFR (estimated glomerular filtration rate) <60mL/min/1.73m2, coagulopathy, hematological disorders, infection at the site of injection, significant psychiatric illnesses (schizophrenia, bipolar, uncontrolled anxiety or depression), narcotic dependency (chronic opioid use of greater than 15mg oral morphine equivalents daily), peripheral neuropathy, pregnancy, patient refusal, lack of informed consent, moderate cognitive impairment, and language or reading barrier. |
Outcome
Primary Outcome Measures
1. Narcotic requirements equivalents [From the time of ICU admission up to 48 hours]
Secondary Outcome Measures
1. Time to extubation [From the time of ICU admission up to 24 hours]
2. Patient satisfaction satisfaction [From extubation up to 48 hours]
3. Pain score equivalents [From the time of ICU admission up to 48 hours]
4. Respiratory rate [After extubation up to 48 hours]
5. Oxygen saturation by pulse oximetry [After extubation up to 48 hours]
Other Outcome Measures
1. Recruitment rate [From the time of first recruitment up to one month]
2. Acceptability [From the time of ICU admission up to 48 hours]
3. Nausea/Vomiting [After extubation up to 48 hours]
